CAS 1282512-48-4

1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-

Description:

1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl- is a complex organic compound characterized by its multi-ring structure and the presence of various functional groups, including pyrazole and triazole moieties. This compound is typically synthesized for its potential biological activity, particularly in pharmaceutical applications. It may exhibit properties such as anti-inflammatory, antimicrobial, or anticancer effects, although specific biological activities would depend on the precise molecular interactions and mechanisms of action. The presence of multiple heterocycles suggests potential for diverse reactivity and interactions with biological targets. Additionally, the compound's solubility, stability, and reactivity can be influenced by its substituents and overall molecular geometry. As with many synthetic organic compounds, safety and handling precautions are essential, and its use would be governed by regulatory guidelines in research and development contexts.

Formula: C₂₄H₂₈N₈O₂

InChI: InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33)

InChI key: InChIKey=BEUQXVWXFDOSAQ-UHFFFAOYSA-N

SMILES: C(C)(C)N1C(C=2N=C3C=4C(=CC(=CC4)C5=CN(C(C(N)=O)(C)C)N=C5)OCCN3C2)=NC(C)=N1

Synonyms:

• 1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-
• GDC 0032
• Taselisib
• RG 7604
• 4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-1H-pyrazole-1-acetamide

1H-Pyrazole-1-acetamide, 4-[5,6-dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-

CAS: 1282512-48-4

Formula: C₂₄H₂₈N₈O₂

Purity: 99%

Color and Shape: Solid

Molecular weight: 460.5315

Ref: IN-DA000XWI

2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4]Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide

CAS: 1282512-48-4

2-(4-(2-(1-Isopropyl-3-Methyl-1H-1,2,4-Triazol-5-Yl)-5,6-Dihydrobenzo[F]Imidazo[1,2-D][1,4]Oxazepin-9-Yl)-1H-Pyrazol-1-Yl)-2-Methylpropanamide

Purity: 98%

Molecular weight: 460.53g/mol

Ref: 54-OR1024385

Taselisib

CAS: 1282512-48-4

Taselisib

Purity: ≥98%

Molecular weight: 460.53g/mol

Ref: 54-BUP12997

9-BROMO-2-(1-ISOPROPYL-3-METHYL-1H-1,2,4-TRIAZOL-5-YL)-5,6-DIHYDROBENZO[F]IMIDAZO[1,2-D][1,4]OXAZEPINE

CAS: 1282512-48-4

Purity: 95.0%

Molecular weight: 388.2690124511719

Ref: 10-F534332

GDC-0032

CAS: 1282512-48-4

Ref: 7W-GW2186

Taselisib

CAS: 1282512-48-4

Taselisib (GDC-0032) is an oral PI3K alpha inhibitor with potential cancer-treating properties.

Formula: C₂₄H₂₈N₈O₂

Purity: 99.62% - 99.79%

Color and Shape: Solid

Molecular weight: 460.53

Ref: TM-T1999

GDC 0032

CAS: 1282512-48-4

Inhibitor of PI3K kinase isoforms α, δ, and γ

Formula: C₂₄H₂₈N₈O₂

Purity: Min. 95%

Molecular weight: 460.53 g/mol

Ref: 3D-BG166285

4-[5,6-Dihydro-2-[3-methyl-1-(1-methylethyl)-1H-1,2,4-triazol-5-yl]imidazo[1,2-d][1,4]benzoxazepin-9-yl]-α,α-dimethyl-1H-pyrazole-1-acetamide-d7

Controlled Product

CAS: 1282512-48-4

Formula: C₂₄H₂₁D₇N₈O₂

Color and Shape: Neat

Molecular weight: 360.361

Ref: TR-D446477